Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This research program is aimed to develop a integrative psychotherapy (including CBT and biofeedback therapy) and to examine its efficacy on treatment of somatic symptom disorder. The study design is a randomized controlled trial with waiting list control. Scores of Patient Health Questionniare-15 and Health Anxiety Questionnaire are the primary endpoints.
Somatic symptom disorder (SSD) is a psychiatric disorder featured with somatic distress and related psychological phenomena. In the past several years, our research team has investigated several aspects of SSD, including psychopathology, epidemiology, mechanism, and diagnostic biomarkers. But the aspect about treatment on SSD has not been comprehensively explored.
In literature, the treatment of SSD can be separated into physical and psychological approaches. The physical approach includes pharmacotherapy and magnetic/electrical neuromodulation. Among several types of psychotherapies, cognitive behavioral therapy (CBT) has the most evidence. Previous studies have disclosed SSD patients to have following cognitive or behavioral features: selective attention on somatic distress; memory bias on the severe health conditions; all-or-none cognition about health; organic attribution style; catastrophizing cognitive pattern about health; high motivation of concerning issues about health; inadequate reassurance-seeking behavior; the assumption about the connection between rest and somatic distress, etc.
Biofeedback therapy works by measuring several biological signals related with stress and relaxation (such as heart rate, skin conductance, electromyography, electroencephalography, and finger temperature); feedback of these signals to the subjects can help them more clearly understand the association between their behavior/cognition and relaxation. Biofeedback therapy has been extensively applied in the psychosomatic field.
This research program is aimed to develop a integrative psychotherapy (including CBT and biofeedback therapy) and to examine its efficacy. The study design is a randomized controlled trial with waiting list control. Scores of Patient Health Questionniare-15 (PHQ-15) and Health Anxiety Questionnaire (HAQ) are the primary endpoints; the changes of other psychological and biological measurements are viewed as secondary endpoints.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Experimental Group | Experimental | The experimental group will receive cognitive-behavioral therapy (CBT) and biofeedback therapy. |
|
| Control Group | No Intervention | The design of control group is waiting list control; their data will be collected without intervention during the observation period. After the observation period, psychotherapy (CBT and biofeedback, the same as intervention) will be arranged. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| cognitive-behavioral therapy and biofeedback therapy | Behavioral | Complete eight sessions of cognitive-behavioral therapy and biofeedback therapy within three months. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Scores of Patient Health Questionnaire-15 (PHQ-15) | Measurement of somatic distress. Score range is 0 to 30; higher score means more severe somatic distress | Week 12 (comparing with the data in week 0) |
| Scores of Health Anxiety Questionnaire (HAQ) | Measurement of health anxiety. Score range is 0 to 63; higher score means more severe health anxiety | Week 12 (comparing with the data in week 0) |
| Measure | Description | Time Frame |
|---|---|---|
| Scores of Beck Depression Inventory-II (BDI-II) | Measurement of depression. Score range is 0 to 63; higher score means more severe depression | Week 12 (comparing with the data in week 0) |
| Scores of Beck Anxiety Inventory (BAI) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Wei-Lieh Huang, MD, PhD | Contact | 886-5-5323911 | 563700 | weiliehhuang@gmail.com |
| Name | Affiliation | Role |
|---|---|---|
| Wei-Lieh Huang, MD, PhD | National Taiwan University Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Department of Psychiatry, National Taiwan University Hospital Yunlin Branch | Recruiting | Yunlin | 640 | Taiwan |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Measurement of anxiety. Score range is 0 to 63; higher score means more severe anxiety
| Week 12 (comparing with the data in week 0) |
| Scores of Cognitions About Body and Health Questionnaire (CABAH) | Measurement of cognitions about health. Score range is 0 to 117; higher score means more severe cognitive distortion about health | Week 12 (comparing with the data in week 0) |
| Heart rate variability | Measurement of parasympathetic activity | Week 12 (comparing with the data in week 0) |
| Skin conductance | Measurement of sympathetic activity | Week 12 (comparing with the data in week 0) |
| ID | Term |
|---|---|
| D015928 | Cognitive Behavioral Therapy |
| D001676 | Biofeedback, Psychology |
| ID | Term |
|---|---|
| D001521 | Behavior Therapy |
| D011613 | Psychotherapy |
| D004191 | Behavioral Disciplines and Activities |
| D026441 | Mind-Body Therapies |
| D000529 | Complementary Therapies |
| D013812 | Therapeutics |
| D030141 | Feedback, Psychological |
Not provided
Not provided